MC2 Therapeutics A/S announces completion of recruitment in US Phase 3 trial in Psoriasis Vulgaris
POSTED: April 2, 2018
- Topline results are expected in Q3 2018
Copenhagen, April 2nd, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that the patient enrollment for the Phase ...
READ FULL ARTICLE >